Goelzer Investment Management Inc. Has $274,000 Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Goelzer Investment Management Inc. lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 56.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,425 shares of the medical equipment provider's stock after selling 3,173 shares during the period. Goelzer Investment Management Inc.'s holdings in Zimmer Biomet were worth $274,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Garde Capital Inc. bought a new stake in Zimmer Biomet during the first quarter worth approximately $29,000. Washington Trust Advisors Inc. bought a new stake in shares of Zimmer Biomet in the 1st quarter worth $30,000. Menard Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $30,000. Accredited Wealth Management LLC acquired a new position in Zimmer Biomet during the fourth quarter worth about $36,000. Finally, OFI Invest Asset Management bought a new stake in Zimmer Biomet in the fourth quarter worth about $40,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Insider Activity

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the transaction, the insider owned 20,424 shares of the company's stock, valued at approximately $1,940,280. This represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ZBH. JPMorgan Chase & Co. decreased their price target on shares of Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Truist Financial set a $101.00 target price on Zimmer Biomet in a report on Tuesday, May 6th. Raymond James Financial cut their target price on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Stifel Nicolaus set a $115.00 price objective on Zimmer Biomet and gave the company a "buy" rating in a research report on Tuesday, May 6th. Finally, Royal Bank Of Canada dropped their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $111.33.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock traded down $1.09 during trading on Monday, reaching $92.58. The company's stock had a trading volume of 1,994,496 shares, compared to its average volume of 1,812,131. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $116.71. The stock has a 50-day moving average price of $94.04 and a two-hundred day moving average price of $101.73. The company has a current ratio of 2.44, a quick ratio of 1.46 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $18.32 billion, a P/E ratio of 20.48, a price-to-earnings-growth ratio of 2.17 and a beta of 0.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The business's revenue for the quarter was up 1.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.94 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.04%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is currently 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.